Recurrent Islet Cell Carcinoma Completed Phase 2 Trials for Temsirolimus (DB06287)

IndicationStatusPhase
DBCOND0028802 (Recurrent Islet Cell Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00093782Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaTreatment